In short. Most compounded prescriptions that come back do so for a handful of fixable reasons: the order is really office stock, the prescriber is not licensed where the patient is, a required element is missing, or the product cannot be sent for that patient. Each can be caught before the prescriber signs.
1. It is office stock, written as a prescription
A 503A compounding pharmacy works from prescriptions for individual patients. FDA says compounding under section 503A “must be based on the receipt of a valid prescription for an identified individual patient.” A prescription written to put product in the office, with no real patient behind it, does not fit that. Office-use supply is its own kind of order, from a 503B outsourcing facility, which FDA says may supply a health care provider without a prescription for an identified patient.
Prevent it: keep patient prescriptions and office-use purchases as separate orders from the start.
2. The prescriber is not licensed in the patient’s state
The prescription travels with the prescriber’s licence. When the patient lives, or the order ships, somewhere the prescriber is not licensed, a pharmacy will usually not fill it. Licences are issued by state boards; NABP keeps the contact list for every state board of pharmacy, and each medical board keeps its own public lookup.
Prevent it: confirm each prescriber’s state licences before an order is written for a patient in that state, and keep expiry dates current.
3. A required element is missing
A prescription that leaves out the patient’s details, the strength, the quantity, the directions or the prescriber’s identifying details will be returned so it can be completed. Pharmacies also commonly need the prescriber’s contact details to reach them with a question. Every round trip adds days.
Prevent it: treat every element as required, and have the prescriber review the whole prescription, as it will be sent, before signing.
4. It looks like a copy of an approved drug
Section 503A says a compounder must not compound “regularly or in inordinate amounts any drug products that are essentially copies of a commercially available drug product.” FDA’s guidance ties the difference to a change that the prescriber has determined will produce a significant difference for the patient. A pharmacy that cannot see a patient-specific reason may ask for one, or decline.
Prevent it: when a compounded version is chosen for a patient-specific reason, the prescriber should record that reason. Whether a given order meets the rule is for the prescriber, the pharmacy and your counsel.
5. The product cannot be sent for that patient
Not every product is available for every state, and some products are not compounded at all. Finding that out after the prescriber has signed and the clinic has paid is the most expensive way to learn it.
Prevent it: know before ordering whether a product can be sent to that patient’s state.
Where TrueRoute fits
TrueRoute is ordering software, not a pharmacy, and never prescribes. Orders are filled by licensed pharmacies in our network. Before a prescription is signed, TrueRoute checks the prescriber’s licence in the patient’s ship-to state as attested, requires the elements a prescription must carry, refuses controlled substances, and says in words when a product cannot be sent for a patient, all before anything is charged. The prescriber reviews the complete prescription with its total, and what is signed is frozen as the record the pharmacy receives. A patient prescription and an office-use purchase are separate orders.
What is a 503A compounding pharmacy? · Choosing a compounding pharmacy · How it works